ArticleBMC pediatrics2025
Methylmalonic acidemia with homocystinuria in acute myeloid leukemia: a case report.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethylmalonic acidaemia (MMA) is a genetic metabolic disorder caused by congenital defects that may result in multisystem damage. However, MMA complicated with acute myeloid leukemia (AML) is very rare. CASE PRESENTATION: Here, we report a case of MMA with AML in a boy aged 7 years and 6 months. The boy was screened for MMA after birth and received long-term treatment with dietary control, vitamin B12, and L-carnitine. He was readmitted at the age of 7 years and 6 months with systemic bleeding spots and was diagnosed with AML by bone marrow cytology. When the diagnosis was clear, the patient received chemotherapy in addition to maintenance treatment for MMA. His blood routine, liver and kidney function, blood biochemistry, blood glucose, blood lipids, lactic acid and blood ammonia were monitored continuously. Bone marrow cytology one month after starting chemotherapy showed complete remission. Sorafenib was also added during chemotherapy and was discontinued 1 year after completion of chemotherapy. At the end of chemotherapy, he chose venetoclax for consolidation, and to date, the patient's condition is stable, with sustained CR and no relapse.
conclusionMMA combined with AML is rare. The prevention of infection, comprehensive assessment of nutritional status, continuous monitoring of related indicators and overall situation should be prioritized and comprehensive and individualized treatment approaches are paramount.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.